Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | MGAM | O43451 | 1/20 | 0.50 |
| ▸ | SI | P14410 | 1/20 | 0.50 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.50 |
| ▸ | DGKA | P23743 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.48 |
| ▸ | PGR | P06401 | 1/20 | 0.48 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.48 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.48 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.48 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.47 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.47 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6623769 | 0.98 | CYP1A2 (0.59) | CYP1A2ALDH1A1GAAHSD17B10ALOX15 | |
| SCHEMBL28663838 | 0.98 | CYP1A2 (0.59) | CYP1A2ALDH1A1GAAHSD17B10ALOX15 | |
| SCHEMBL16022550 | 0.98 | CYP1A2 (0.59) | CYP1A2ALDH1A1GAAHSD17B10ALOX15 | |
| SCHEMBL6823809 | 0.98 | CYP1A2 (0.59) | CYP1A2ALDH1A1GAAHSD17B10ALOX15 | |
| SCHEMBL10534701 | 0.98 | CYP1A2 (0.59) | CYP1A2ALDH1A1GAAHSD17B10ALOX15 | |
| SCHEMBL723390 | 0.95 | CYP1A2 (0.61) | CYP1A2ALDH1A1GAAHSD17B10ALOX15 | |
| Ethylene SCHEMBL11466234 | 0.94 | CYP1A2 (0.55) | CYP1A2ALDH1A1GAAHSD17B10ALOX15 | |
| Ethane SCHEMBL11195854 | 0.93 | CYP1A2 (0.59) | CYP1A2ALDH1A1GAAHSD17B10ALOX15 | |
| 2-Nonanone SCHEMBL28983324 | 0.92 | DGKA (0.64) | CYP1A2ALDH1A1DGKATSHRLMNA | |
| SCHEMBL8570508 | 0.90 | CYP1A2 (0.73) | CYP1A2ALDH1A1GAAHSD17B10ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12390463-B2 | Dosage forms and regimens for amino acid compounds | PLIANT THERAPEUTICS, INC. (US) | 2025-08-19 | — | — | US | disclosed |
| US-20250223288-A1 | AMINO ACID COMPOUNDS AND METHODS OF USE | PLIANT THERAPEUTICS, INC. | 2025-07-10 | — | — | US | disclosed |
| CN-120091811-A | Integrin inhibitors and their use in combination with other agents | 普利安特治疗公司 | 2025-06-03 | — | — | CN | disclosed |
| EP-4551204-A2 | INTEGRIN INHIBITORS AND USES THEREOF IN COMBINATION WITH OTHER AGENTS | Pliant Therapeutics, Inc. (US) | 2025-05-14 | — | — | EP | disclosed |
| EP-4525866-A1 | STABILIZATION OF INTEGRIN INHIBITORS | Pliant Therapeutics, Inc. (US) | 2025-03-26 | — | — | EP | disclosed |
| EP-4520329-A2 | TREATMENT OF RESPIRATORY DISEASES WITH AMINO ACID COMPOUNDS | Pliant Therapeutics, Inc. (US) | 2025-03-12 | — | — | EP | disclosed |
| EP-4509512-A2 | AMINO ACID COMPOUNDS AND METHODS OF USE | Pliant Therapeutics, Inc. (US) | 2025-02-19 | — | — | EP | disclosed |
| CN-118401521-A | Integrin inhibitors and their use in combination with other agents | 普利安特治疗公司 | 2024-07-26 | — | — | CN | disclosed |
| US-20240140888-A1 | COMPOSITION COMPRISING AN ALKANE AND AN OXOESTER | BIOSYNTHIS (FR) | 2024-05-02 | — | — | US | disclosed |
| US-20240122930-A1 | INTEGRIN INHIBITORS AND USES THEREOF IN COMBINATION WITH OTHER AGENTS | PLIANT THERAPEUTICS, INC. | 2024-04-18 | — | — | US | disclosed |
| US-20110027882-A1 | Methods and Compositions for Treating Neurological Disease | UNIVERSITY OF MASSACHUSETTS | 2011-02-03 | — | — | US | disclosed |
| US-20080221070-A1 | METHODS AND COMPOUNDS FOR THE TARGETED DELIVERY OF AGENTS TO BONE FOR INTERACTION THEREWITH | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION | 2008-09-11 | — | — | US | disclosed |
| US-20070093465-A1 | Cephem compound | DSM IP ASSETS B.V. (NL) | 2007-04-26 | — | — | US | disclosed |
| US-5925680-A | Synthetic excitatory amino acids | ELI LILLY AND COMPANY (US) | 1999-07-20 | — | — | US | disclosed |
| US-5925782-A | Synthetic excitatory amino acids | ELI LILLY AND COMPANY (US) | 1999-07-20 | — | — | US | disclosed |
| US-5750566-A | NERVOUS SYSTEM DISORDERS; PSYCHOLOGICAL DISORDERS | ELI LILLY AND COMPANY (US) | 1998-05-12 | — | — | US | disclosed |
| US-4769482-A | Cyano and thiocyano intermediates | ELI LILLY AND COMPANY (US) | 1988-09-06 | — | — | US | disclosed |
| EP-0108592-B1 | LEUKOTRIENE ANTAGONISTS | ELI LILLY AND COMPANY (US) | 1987-09-30 | — | — | EP | disclosed |
| US-4661505-A | 4-(4-ACETYL-3-HYDROXY-2-PROPYLPHENOXY) ALKANOIC ACIDS, TETRAZOLES, AND DERIVATIVES | ELI LILLY AND COMPANY (US) | 1987-04-28 | — | — | US | disclosed |
| EP-0108592-A1 | Leukotriene antagonists | ELI LILLY AND COMPANY (US) | 1984-05-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240140888-A1 | COMPOSITION COMPRISING AN ALKANE AND AN OXOESTER | ALKBH2, ABHD12, FAAH2 | CYP1A2 163/4885ALDH1A1 938/4885GAA 4071/4885 |
| US-20080221070-A1 | METHODS AND COMPOUNDS FOR THE TARGETED DELIVERY OF AGENTS TO BONE FOR INTERACTION THEREWITH | SHBG, ESRRA, ESRRG | CYP1A2 2384/4885ALDH1A1 2993/4885GAA 2717/4885 |
| US-12390463-B2 | Dosage forms and regimens for amino acid compounds | ITGB6, ITGA6, ITGAV | CYP1A2 3905/4885ALDH1A1 3476/4885GAA 4698/4885 |
| US-20240122930-A1 | INTEGRIN INHIBITORS AND USES THEREOF IN COMBINATION WITH OTHER AGENTS | ITGB6, ITGA6, ITGAV | CYP1A2 3904/4885ALDH1A1 1094/4885GAA 4360/4885 |
| US-20070093465-A1 | Cephem compound | HCCS, PCCA, CPS1 | CYP1A2 190/4885ALDH1A1 685/4885GAA 2893/4885 |
| US-20250223288-A1 | AMINO ACID COMPOUNDS AND METHODS OF USE | ITGB6, ITGA6, ITGA5 | CYP1A2 4533/4885ALDH1A1 3834/4885GAA 4675/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.